Laurel Grove Capital Has Lowered Bank Of America (BAC) Holding By $609,000; Progenics Pharmaceuticals, Inc. (PGNX) Had 5 Bullish Analysts

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Logo

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. Needham upgraded Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) rating on Monday, February 6. Needham has “Strong Buy” rating and $14 target. The company was downgraded on Friday, August 7 by Zacks. The rating was maintained by Jefferies with “Buy” on Tuesday, September 26. Brean Capital maintained the shares of PGNX in report on Thursday, August 6 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Friday, October 23. The firm earned “Buy” rating on Wednesday, August 9 by Cantor Fitzgerald. As per Tuesday, June 20, the company rating was maintained by Needham. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Aegis Capital on Thursday, October 27. The rating was maintained by Needham on Friday, August 7 with “Buy”. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Thursday, June 8 by Jefferies. See Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) latest ratings:

Laurel Grove Capital Llc decreased Bank Of America Corp (BAC) stake by 51.53% reported in 2017Q4 SEC filing. Laurel Grove Capital Llc sold 21,000 shares as Bank Of America Corp (BAC)’s stock declined 1.20%. The Laurel Grove Capital Llc holds 19,750 shares with $583,000 value, down from 40,750 last quarter. Bank Of America Corp now has $306.62B valuation. The stock increased 2.04% or $0.6 during the last trading session, reaching $29.99. About 65.68M shares traded. Bank of America Corporation (NYSE:BAC) has risen 28.18% since March 31, 2017 and is uptrending. It has outperformed by 16.63% the S&P500.

The stock increased 1.22% or $0.09 during the last trading session, reaching $7.46. About 992,648 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has declined 32.66% since March 31, 2017 and is downtrending. It has underperformed by 44.21% the S&P500.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $542.06 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

Investors sentiment increased to 1.22 in Q4 2017. Its up 0.11, from 1.11 in 2017Q3. It improved, as 11 investors sold Progenics Pharmaceuticals, Inc. shares while 40 reduced holdings. 22 funds opened positions while 40 raised stakes. 56.89 million shares or 3.42% less from 58.90 million shares in 2017Q3 were reported. Ls Invest Ltd Com owns 2,272 shares or 0% of their US portfolio. Susquehanna Intll Grp Llp has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). The Switzerland-based Swiss National Bank has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Millennium Management Limited Liability Company owns 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 28,385 shares. Phocas Fincl reported 0.72% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). 3,581 were reported by Panagora Asset Management. Sector Pension Inv Board holds 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) or 44,457 shares. Bnp Paribas Arbitrage stated it has 29,113 shares or 0% of all its holdings. First Republic Inv Mngmt accumulated 21,802 shares. Opus Point Partners Limited Liability reported 0.11% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Voya Invest Mngmt Limited Company has 35,657 shares for 0% of their portfolio. Gradient Investments Ltd Limited Liability Company holds 0.03% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 74,192 shares. Los Angeles Cap Mgmt Equity Rech holds 0% or 28,770 shares. Great West Life Assurance Can has 98,958 shares. Fisher Asset Mgmt Limited Com holds 0% or 303,692 shares in its portfolio.

Among 33 analysts covering Bank of America (NYSE:BAC), 22 have Buy rating, 0 Sell and 11 Hold. Therefore 67% are positive. Bank of America had 108 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was upgraded by CLSA on Friday, January 29 to “Outperform”. The rating was maintained by Keefe Bruyette & Woods with “Buy” on Thursday, December 21. Nomura maintained Bank of America Corporation (NYSE:BAC) rating on Monday, October 16. Nomura has “Buy” rating and $30 target. Renaissance Macro Securities LLC maintained the stock with “Buy” rating in Sunday, July 23 report. The firm has “Buy” rating given on Wednesday, August 30 by RBC Capital Markets. The stock of Bank of America Corporation (NYSE:BAC) earned “Hold” rating by Standpoint Research on Thursday, December 1. Robert W. Baird maintained Bank of America Corporation (NYSE:BAC) rating on Tuesday, January 2. Robert W. Baird has “Hold” rating and $30.0 target. Oppenheimer maintained the stock with “Buy” rating in Tuesday, July 18 report. BMO Capital Markets maintained it with “Hold” rating and $29.0 target in Friday, October 13 report. The firm has “Hold” rating by BMO Capital Markets given on Tuesday, July 18.

Investors sentiment increased to 1.19 in 2017 Q4. Its up 0.15, from 1.04 in 2017Q3. It is positive, as 66 investors sold BAC shares while 561 reduced holdings. 162 funds opened positions while 585 raised stakes. 6.85 billion shares or 0.98% less from 6.91 billion shares in 2017Q3 were reported. 405,470 are held by Greylin Investment Mangement. Fort Washington Inv Advsrs Inc Oh owns 3.88M shares. Haverford Service Incorporated reported 0.14% in Bank of America Corporation (NYSE:BAC). Gw Henssler And Assocs Limited reported 0.02% of its portfolio in Bank of America Corporation (NYSE:BAC). Comerica Securities owns 10,816 shares or 0.04% of their US portfolio. Citadel Llc reported 32.50 million shares. 1,554 are owned by Contravisory Investment Mngmt Inc. Manikay Prtn Ltd Liability Corporation reported 4.50M shares stake. Modera Wealth Mgmt Limited Liability Co stated it has 48,880 shares or 0.31% of all its holdings. Bridgeway Cap owns 4.25 million shares. Wellington Gp Limited Liability Partnership owns 189.71M shares. Shoker Inv Counsel Inc holds 0.36% of its portfolio in Bank of America Corporation (NYSE:BAC) for 17,017 shares. Agf Invests Incorporated holds 0.03% or 120,000 shares in its portfolio. Nomura Asset Mngmt Limited has invested 0.6% in Bank of America Corporation (NYSE:BAC). Scott Selber Inc accumulated 2.11% or 133,463 shares.

Bank of America Corporation (NYSE:BAC) Institutional Positions Chart